AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02494856
Drug: Surgery with Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
Trial: NCT02494856
Drug: Surgery with Naproxen and Esomeprazole
RxNorm normalized name: naproxen and esomeprazole
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
Trial: NCT01673984
Drug: Decapeptyl® SR 22.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
Trial: NCT01673984
Drug: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Trial: NCT00943397
Drug: Comparator: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
Trial: NCT04552600
Drug: Nuvastatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b Interventional, multi-centered, double-masked, randomized
Trial: NCT01468454
Drug: 18 F-DOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
Trial: NCT02750696
Drug: Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Trial: NCT02750696
Drug: Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group received opioid/ non-opioid analgesic combination.
Trial: NCT01384747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
Trial: NCT01995344
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01720524
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
Trial: NCT02183012
Drug: Ibuprofen extrudate
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01012999
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
Trial: NCT02183012
Drug: Ibuprofen lysinate
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02183012
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01850394
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Trial: NCT01488552
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Trial: NCT01488552
Drug: mFOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Trial: NCT00107757
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04158453
Drug: AUT00201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of AUT00201
Trial: NCT04158453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of placebo
Trial: NCT01745380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
Trial: NCT01193283
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 my/kg for 4 days
Trial: NCT00803335
Drug: Vaginal conjugated estrogen cream 0.5gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
Trial: NCT00803335
Drug: Vaginal conjugated estrogen cream 1.0gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
Trial: NCT01502202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
Trial: NCT00549549
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indomethacin 50 mg three times a day (TID) for 8 days.
Trial: NCT00549549
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
Trial: NCT00549549
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
Trial: NCT00549549
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 50 mg two times a day (BID) for 8 days
Trial: NCT01509612
Drug: Additive classical homeopathy
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic remedies every 2 to 3 months
Trial: NCT01509612
Drug: Homeopathic Placebo globules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic placebo globules every 2 to 3 months
Trial: NCT04271514
Drug: RPT193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antagonist of the CCR4 chemokine receptor
Trial: NCT04271514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00649077
Drug: Meloxicam Tablets 15 mg
RxNorm normalized name: meloxicam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fasting
Trial: NCT00649077
Drug: Mobic® Tablets 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, single dose fasting
Trial: NCT02288819
Drug: Loop diuretic downtitration
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved.
Trial: NCT02169843
Drug: Placebo(for Dexmedetomidine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
Trial: NCT01918657
Drug: walnut powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
Trial: NCT01918657
Drug: walnut powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalating doses of walnut powder
Trial: NCT02510612
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
Trial: NCT01372826
Drug: NKTR118 Group1
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT01372826
Drug: NKTR118 Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT01372826
Drug: NKTR118 Group3
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT01372826
Drug: NKTR118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, 25 mg
Trial: NCT02266589
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Trial: NCT02824627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive substance administered in volume equivalent to volume administered in active treatment arm.
Trial: NCT04303195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03202446
Drug: 1% Glycated Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202446
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03202446
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216279
Drug: PulmoBind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
Trial: NCT03099603
Drug: HTD1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small molecular compound for the treatment of primary sclerosing cholangitis
Trial: NCT01074177
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day
Trial: NCT00870467
Drug: Double-blind Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
Trial: NCT00691288
Drug: Omega Pure followed by placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
Trial: NCT00691288
Drug: Placebo followed by Omega Pure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Trial: NCT01454011
Drug: Testosterone 50mg transdermal application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of testosterone 50mg transdermal gel in every night
Trial: NCT00003925
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000256
Drug: 80% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01070433
Drug: MEBO Wound Ointment (MEBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application twice a day
Trial: NCT01878318
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: stable dose
Trial: NCT02426034
Drug: ApatinibTablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Tablets, recommended dose of 850mg
Trial: NCT03009877
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
Trial: NCT04350645
Drug: Normal Saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mls normal saline 0.9% over 2 minutes
Trial: NCT00498953
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00470171
Drug: Ursodesoxycholic acid
RxNorm normalized name: Tauroursodesoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00418028
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01153607
Drug: BAY1006578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Trial: NCT01153607
Drug: BAY1006578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Trial: NCT01153607
Drug: BAY1006578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
Trial: NCT02711358
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
Trial: NCT01545141
Drug: Chemokin Modulatory Regimen (5 MU/m2)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
Trial: NCT01545141
Drug: Chemokin Modulatory Regimen (10 MU/m2)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Trial: NCT01545141
Drug: Chemokin Modulatory Regimen (20 MU/m2)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Trial: NCT04041921
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00540670
Drug: E5555 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5555 100 mg (tablet) taken orally, once a day.
Trial: NCT00540670
Drug: E5555 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5555 200 mg (tablet) taken orally, once a day.
Trial: NCT00540670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet) taken orally, once a day.
Trial: NCT04019145
Drug: EverX Posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fiber reinforced bulk fill resin composite
Trial: NCT04019145
Drug: Resins, Composite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: incremental packing of Nanohybrid Resin composite
Trial: NCT04378569
Drug: ARQ-252 cream 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-252 cream 0.3%
Trial: NCT04378569
Drug: ARQ-252 cream 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-252 cream 0.1%
Trial: NCT04378569
Drug: ARQ-252 Vehicle Cream
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-252 Vehicle Cream
Trial: NCT01844817
Drug: OGX-427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Trial: NCT01844817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Trial: NCT00001296
Drug: tumor necrosis factor
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02252302
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Trial: NCT03114085
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Trial: NCT02402465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated by placebo
Trial: NCT03263715
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly administration of Placebo subcutaneous from Baseline to Week 16.
Trial: NCT00991029
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 8 tablets followed by one tablet daily for 89 days
Trial: NCT02720081
Drug: MK-1029 150 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tablet administered orally, once a day (QD), at bedtime
Trial: NCT02720081
Drug: MK-1029 Matching-image Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-image placebo tablet administered orally, QD, at bedtime
Trial: NCT02845375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Trial: NCT03263715
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
Trial: NCT03654729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution in 20 mL single dose glass vials
Trial: NCT01655992
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2500mg／m2／day divided into twice two weeks on one week off
Trial: NCT01655992
Drug: S1 generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg／m2 bid four weeks on two weeks off
Trial: NCT04481594
Drug: HPN-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
Trial: NCT04481594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
Trial: NCT00052078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were treated with a placebo pill.